An updated review of SARS‐CoV‐2 detection methods in the context of a novel coronavirus pandemic
Abstract The World Health Organization has reported approximately 430 million confirmed cases of coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), worldwide, including nearly 6 million deaths, since its initial appearance in China in 2019. W...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Bioengineering & Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/btm2.10356 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846161783366090752 |
|---|---|
| author | Yuxuan Zhang Zhiwei Huang Jiajie Zhu Chaonan Li Zhongbiao Fang Keda Chen Yanjun Zhang |
| author_facet | Yuxuan Zhang Zhiwei Huang Jiajie Zhu Chaonan Li Zhongbiao Fang Keda Chen Yanjun Zhang |
| author_sort | Yuxuan Zhang |
| collection | DOAJ |
| description | Abstract The World Health Organization has reported approximately 430 million confirmed cases of coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), worldwide, including nearly 6 million deaths, since its initial appearance in China in 2019. While the number of diagnosed cases continues to increase, the need for technologies that can accurately and rapidly detect SARS‐CoV‐2 virus infection at early phases continues to grow, and the Federal Drug Administration (FDA) has licensed emergency use authorizations (EUAs) for virtually hundreds of diagnostic tests based on nucleic acid molecules and antigen–antibody serology assays. Among them, the quantitative real‐time reverse transcription PCR (qRT‐PCR) assay is considered the gold standard for early phase virus detection. Unfortunately, qRT‐PCR still suffers from disadvantages such as the complex test process and the occurrence of false negatives; therefore, new nucleic acid detection devices and serological testing technologies are being developed. However, because of the emergence of strongly infectious mutants of the new coronavirus, such as Alpha (B.1.1.7), Delta (B.1.617.2), and Omicron (B.1.1.529), the need for the specific detection of mutant strains is also increasing. Therefore, this article reviews nucleic acid‐ and antigen–antibody‐based serological assays, and compares the performance of some of the most recent FDA‐approved and literature‐reported assays and associated kits for the specific testing of new coronavirus variants. |
| format | Article |
| id | doaj-art-d5d94ba8cf2e455d95e67a0cdde31d42 |
| institution | Kabale University |
| issn | 2380-6761 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Bioengineering & Translational Medicine |
| spelling | doaj-art-d5d94ba8cf2e455d95e67a0cdde31d422024-11-21T05:16:02ZengWileyBioengineering & Translational Medicine2380-67612023-01-0181n/an/a10.1002/btm2.10356An updated review of SARS‐CoV‐2 detection methods in the context of a novel coronavirus pandemicYuxuan Zhang0Zhiwei Huang1Jiajie Zhu2Chaonan Li3Zhongbiao Fang4Keda Chen5Yanjun Zhang6Shulan International Medical College, Zhejiang Shuren University Hangzhou ChinaSchool of Laboratory Medicine and Life Sciences Wenzhou Medical University Wenzhou ChinaShulan International Medical College, Zhejiang Shuren University Hangzhou ChinaShulan International Medical College, Zhejiang Shuren University Hangzhou ChinaShulan International Medical College, Zhejiang Shuren University Hangzhou ChinaShulan International Medical College, Zhejiang Shuren University Hangzhou ChinaZhejiang Provincial Center for Disease Control and Prevention Hangzhou ChinaAbstract The World Health Organization has reported approximately 430 million confirmed cases of coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), worldwide, including nearly 6 million deaths, since its initial appearance in China in 2019. While the number of diagnosed cases continues to increase, the need for technologies that can accurately and rapidly detect SARS‐CoV‐2 virus infection at early phases continues to grow, and the Federal Drug Administration (FDA) has licensed emergency use authorizations (EUAs) for virtually hundreds of diagnostic tests based on nucleic acid molecules and antigen–antibody serology assays. Among them, the quantitative real‐time reverse transcription PCR (qRT‐PCR) assay is considered the gold standard for early phase virus detection. Unfortunately, qRT‐PCR still suffers from disadvantages such as the complex test process and the occurrence of false negatives; therefore, new nucleic acid detection devices and serological testing technologies are being developed. However, because of the emergence of strongly infectious mutants of the new coronavirus, such as Alpha (B.1.1.7), Delta (B.1.617.2), and Omicron (B.1.1.529), the need for the specific detection of mutant strains is also increasing. Therefore, this article reviews nucleic acid‐ and antigen–antibody‐based serological assays, and compares the performance of some of the most recent FDA‐approved and literature‐reported assays and associated kits for the specific testing of new coronavirus variants.https://doi.org/10.1002/btm2.10356nucleic acid molecular testSARS‐CoV‐2serological testtest kit evaluationviral variantsvirus detection |
| spellingShingle | Yuxuan Zhang Zhiwei Huang Jiajie Zhu Chaonan Li Zhongbiao Fang Keda Chen Yanjun Zhang An updated review of SARS‐CoV‐2 detection methods in the context of a novel coronavirus pandemic Bioengineering & Translational Medicine nucleic acid molecular test SARS‐CoV‐2 serological test test kit evaluation viral variants virus detection |
| title | An updated review of SARS‐CoV‐2 detection methods in the context of a novel coronavirus pandemic |
| title_full | An updated review of SARS‐CoV‐2 detection methods in the context of a novel coronavirus pandemic |
| title_fullStr | An updated review of SARS‐CoV‐2 detection methods in the context of a novel coronavirus pandemic |
| title_full_unstemmed | An updated review of SARS‐CoV‐2 detection methods in the context of a novel coronavirus pandemic |
| title_short | An updated review of SARS‐CoV‐2 detection methods in the context of a novel coronavirus pandemic |
| title_sort | updated review of sars cov 2 detection methods in the context of a novel coronavirus pandemic |
| topic | nucleic acid molecular test SARS‐CoV‐2 serological test test kit evaluation viral variants virus detection |
| url | https://doi.org/10.1002/btm2.10356 |
| work_keys_str_mv | AT yuxuanzhang anupdatedreviewofsarscov2detectionmethodsinthecontextofanovelcoronaviruspandemic AT zhiweihuang anupdatedreviewofsarscov2detectionmethodsinthecontextofanovelcoronaviruspandemic AT jiajiezhu anupdatedreviewofsarscov2detectionmethodsinthecontextofanovelcoronaviruspandemic AT chaonanli anupdatedreviewofsarscov2detectionmethodsinthecontextofanovelcoronaviruspandemic AT zhongbiaofang anupdatedreviewofsarscov2detectionmethodsinthecontextofanovelcoronaviruspandemic AT kedachen anupdatedreviewofsarscov2detectionmethodsinthecontextofanovelcoronaviruspandemic AT yanjunzhang anupdatedreviewofsarscov2detectionmethodsinthecontextofanovelcoronaviruspandemic AT yuxuanzhang updatedreviewofsarscov2detectionmethodsinthecontextofanovelcoronaviruspandemic AT zhiweihuang updatedreviewofsarscov2detectionmethodsinthecontextofanovelcoronaviruspandemic AT jiajiezhu updatedreviewofsarscov2detectionmethodsinthecontextofanovelcoronaviruspandemic AT chaonanli updatedreviewofsarscov2detectionmethodsinthecontextofanovelcoronaviruspandemic AT zhongbiaofang updatedreviewofsarscov2detectionmethodsinthecontextofanovelcoronaviruspandemic AT kedachen updatedreviewofsarscov2detectionmethodsinthecontextofanovelcoronaviruspandemic AT yanjunzhang updatedreviewofsarscov2detectionmethodsinthecontextofanovelcoronaviruspandemic |